My Clinical Approach
In everyday urological practice, the most common mistake with overactive bladder is treating it as a single, uniform label. It is not. The right approach is not to prescribe a medication quickly because a patient voids frequently.
The first step is to establish whether this truly is overactive bladder syndrome, or whether an infection, obstruction, retention, stone, metabolic problem, or other urological pathology is behind the symptoms. This reasoning is fully consistent with the most recent EAU guidelines.
My view is that the greatest progress in OAB management is not simply having more drugs or more advanced interventions. It is that we now know far better who needs only proper behavioural bladder retraining, who needs medication, and who should proceed to botulinum toxin or neuromodulation. Good medicine here means selecting the right treatment for the right patient — not the same solution for everyone.
What Is Overactive Bladder?
Overactive bladder (OAB) is defined by the International Continence Society as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology. The key point is that this is primarily a symptom-based diagnosis — not a diagnosis that rests automatically on a single test.
Two forms are generally distinguished:
OAB dry
Urgency is present without urine leakage.
OAB wet
Urgency is accompanied by urgency urinary incontinence.
OAB is a chronic condition that can significantly affect quality of life, often limiting sleep, mobility, work, and social activity.
Symptoms
The most common symptoms of overactive bladder are:
- Sudden, intense, and difficult-to-defer urge to void (urgency)
- Increased daytime urinary frequency
- Nocturia — repeated need to void during the night
- Sometimes urine leakage before reaching the toilet (urgency urinary incontinence)
When to see a urologist promptly
More urgent specialist assessment is needed when urgency is accompanied by:
- Blood in the urine
- Pain or burning on urination
- Recurrent urinary tract infections
- Difficulty starting urination or sensation of incomplete emptying
- Pelvic or suprapubic pain
- Marked worsening or significant nocturia
- Neurological symptoms or known neurological condition
What Must Be Ruled Out First
Overactive bladder is not synonymous with every case of urinary frequency or urgency. Before the diagnosis is made, urinary tract infection, haematuria from another cause, bladder stones, and other causes of bladder storage or voiding dysfunction must be excluded.
For example, cystitis is associated with dysuria and bladder infection, while bladder stones may cause frequency, haematuria, dysuria, or suprapubic pain.
In practice, when there is burning on urination, cloudy or malodorous urine, blood in the urine, fever, suprapubic or loin pain, the OAB label should not be applied automatically without further investigation.
In men, symptoms may coexist with prostatic conditions or bladder outlet obstruction.
Correct Diagnosis Today
Correct diagnosis begins with a targeted history, clinical examination, a bladder/voiding diary, and urinalysis. The EAU guidelines for women state that bladder diaries of 3 to 7 days are reliable tools in the initial assessment, and that at least a three-day bladder diary should be requested from the first evaluation in OAB.
In men, the EAU also recommends clinical examination, urinalysis, and post-void residual measurement when assessing LUTS, because the differential diagnosis is multifactorial and may include prostatic disease, obstruction, retention, or a combination of storage and voiding symptoms.
Which Tests Are Really Needed?
In overactive bladder, the most useful initial tests are usually:
- Bladder diary — At least 3 days — a core tool of the initial assessment.
- Urinalysis — To exclude infection or haematuria.
- Clinical examination — Targeted, according to sex and symptoms.
- Post-void residual measurement — Where clinically indicated, particularly in men or when obstruction is suspected.
What is not needed as routine for everyone
Current guidelines emphasise that urodynamic confirmation of detrusor overactivity does not change treatment outcomes in OAB and that routine urodynamic testing should not be performed before offering first-line treatment in patients with uncomplicated OAB symptoms. Routine upper or lower urinary tract imaging is also not recommended at initial assessment beyond post-void residual where needed.
Treatment: The Right Sequence
First line: bladder training and conservative management
The EAU identifies bladder training as the first-line treatment for adults with OAB/urgency urinary incontinence. NICE also states that women with urgency or mixed urinary incontinence should be offered bladder training for at least 6 weeks as first-line management.
Alongside training, guidelines recommend reviewing and modifying lifestyle factors:
- Caffeine reduction — may improve urgency and frequency
- Review of fluid type and volume
- Weight loss when excess weight or obesity is present
Pharmacological treatment
If conservative management is insufficient, the next step is pharmacological treatment. EAU guidelines for women recommend antimuscarinics and beta-3 agonists when conservative therapy has failed. Antimuscarinics are effective but are associated with dry mouth, constipation, and the risk of cognitive adverse effects. Beta-3 agonists are equally effective with lower rates of dry mouth.
NICE is particularly specific regarding ongoing monitoring: when antimuscarinics are prescribed, incomplete voiding, cognitive burden, dementia, and total anticholinergic load must be taken into account. NICE also recommends reassessment approximately 4 weeks after starting a new OAB medication.
Recent development (NICE TA999, 2024)
NICE added vibegron as a treatment option for adults with OAB symptoms when antimuscarinics are not suitable, insufficiently effective, or have intolerable side effects. Mirabegron remains an established beta-3 agonist option.Postmenopausal women
In women who have OAB symptoms alongside urogenital symptoms of menopause, NICE recommends topical vaginal oestrogens. However, NICE does not recommend systemic hormone replacement therapy specifically for the treatment of incontinence or overactive bladder.
When symptoms persist despite pharmacological treatment
When conservative and pharmacological treatment are insufficient, the current advanced options are:
- Posterior tibial nerve stimulation (PTNS) — Strong EAU recommendation as an option for symptom improvement.
- Intravesical onabotulinumtoxinA 100 U — For refractory OAB/UUI — patients must be counselled on risk of UTI, increased residual, and possible need for intermittent self-catheterisation.
- Sacral nerve stimulation — For patients refractory to antimuscarinics.
NICE states that in women proceeding to invasive treatment for OAB, urodynamic investigation should be performed first to confirm detrusor overactivity.
What Applies in Men
In men, overactive bladder symptoms frequently coexist with other forms of LUTS, particularly prostatic problems or bladder outlet obstruction. It is therefore incorrect to assume automatically that every case of frequency or urgency in a man is "only the prostate" or "only OAB".
EAU guidelines for men state that antimuscarinics and beta-3 agonists are first-line pharmacological options for urgency urinary incontinence when conservative therapy has failed.
Additionally, in men with persistent storage LUTS after alpha-1 blocker monotherapy, a combination of alpha-1 blocker + beta-3 agonist may be used.
Frequently Asked Questions
Is overactive bladder the same as urinary incontinence?
No. Overactive bladder is a symptom syndrome. It may exist with or without urine leakage. When leakage occurs before the person reaches the toilet, that is called urgency urinary incontinence (OAB wet).
Is urodynamic testing always needed?
No. In uncomplicated overactive bladder, guidelines do not recommend routine urodynamic testing before starting first-line treatment. Urodynamics has a greater role when invasive options are being considered or when the clinical picture is more complex.
What is the first-line treatment?
First-line treatment is usually bladder training, fluid and caffeine adjustment, and general lifestyle modification. If that is not sufficient, medication follows.
What happens if the first medication does not work?
Reassessment is performed. The medication may be changed, a different drug class tried, the total anticholinergic burden evaluated, or a beta-3 agonist such as mirabegron or, where appropriate, vibegron considered.
When are botulinum toxin injections or neuromodulation considered?
When overactive bladder persists despite adequate conservative and pharmacological treatment. Options that then come into consideration include PTNS, intravesical onabotulinumtoxinA, and sacral nerve stimulation.
Related Topics
Book Your Appointment in Rhodes
If you are experiencing overactive bladder symptoms affecting your quality of life, a proper urological assessment is essential. The right diagnosis — and the choice of the appropriate treatment — is always individualised.
References – Sources
- EAU Guidelines on Non-neurogenic Female LUTS (2025) — uroweb.org
- EAU Guidelines on Non-neurogenic Male LUTS (2025) — uroweb.org
- NICE NG123: Urinary incontinence and pelvic organ prolapse in women — nice.org.uk
- NICE TA999: Vibegron for treating overactive bladder (2024) — nice.org.uk
Medical review
Dr Marinos Vasilas, Urologist – Andrologist
Dr Marinos Vasilas practises private urology in Rhodes, providing specialist care across the full spectrum of urology and andrology. With a focus on modern diagnostics, evidence-based medicine, and individualised management, he helps patients understand conditions such as overactive bladder and follow a realistic and effective treatment plan.
View full profile
